发明名称 |
Uses of soluble CTLA4 (cytotoxic T-lymphocyte-associated protein 4) fusion molecules mutated from wild-type CTLA4 to retain the ability to bind CD80 and/or CD86 |
摘要 |
Described are soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4 per gram. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 regions are mutated. The mutant molecules described may also include a second amino acid sequence that increases the solubility of the mutant molecule.
|
申请公布号 |
NZ522031(A) |
申请公布日期 |
2006.01.27 |
申请号 |
NZ20010522031 |
申请日期 |
2001.05.23 |
申请人 |
BRISTOL-MYERS SQUIBB COMPANY |
发明人 |
PEACH, ROBERT J;NAEMURA, JOSEPH R;LINSLEY, PETER S;BAJORATH, JURGEN |
分类号 |
C07K16/00;(IPC1-7):C07K14/705 |
主分类号 |
C07K16/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|